Drug Reduces Hospitalizations for Kids with Sickle Cell Anemia
(Ivanhoe Newswire) –A drug that is proven to be effective for treating adults and children with sickle cell anemia has also reduced hospitalizations and cut annual estimated medical costs by 21 percent for affected infants and toddlers, according to researchers at St. Jude Children’s Research Hospital.
The study is the largest ever focusing on the economic impact of the drug hydroxyurea in children with sickle cell anemia. The results showed that hydroxyurea was associated with higher outpatient costs, but lowered overall expenditures. Children on the drug were hospitalized 232 times during the study, compared to 324 hospitalizations for those who were given the placebo. The estimated annual treatment cost was $11,072, compared to $13,962 for children who received the placebo.
For more information, go to:
http://www.stjude.org/stjude/v/index.jsp?vgnextoid=c00544f14c0d0410VgnVCM100000290115acRCRD&vgnextchannel=2e2c338b30b6b310VgnVCM100000290115acRCRD&SearchUrl=search_results.jsp&QueryText=Drug reduces hospitalizations and cost of treating young children with sickle cell anemia
SOURCE: Pediatrics, September 2013
Click Here for a free weekly email with Ivanhoe's latest Medical Breakthroughs.